naltrexone has been researched along with desipramine in 26 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (11.54) | 18.7374 |
1990's | 7 (26.92) | 18.2507 |
2000's | 8 (30.77) | 29.6817 |
2010's | 7 (26.92) | 24.3611 |
2020's | 1 (3.85) | 2.80 |
Authors | Studies |
---|---|
Strassburg, CP; Tukey, RH | 1 |
Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
Topliss, JG; Yoshida, F | 1 |
Adkison, KK; Humphreys, JE; Mahar Doan, KM; Polli, JW; Serabjit-Singh, CJ; Shampine, LJ; Webster, LO; Wring, SA | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Dalvie, D; Loi, CM; Smith, DA | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Mello, NK | 1 |
Insel, TR; Winslow, JT | 1 |
O'Neill, KA; Valentino, D | 1 |
Mayer, DJ; Watkins, LR | 1 |
Mello, NK; Mendelson, JH | 1 |
Barg, J; Belcheva, MM; Coscia, CJ; Johnson, FE; Levy, R; McHale, RJ; Saya, D; Vogel, Z; Zimlichman, R | 1 |
Hirokami, M; Ikeda, T; Matsumoto, M; Saito, H; Smith, CB; Tochihara, M; Togashi, H; Yoshioka, M | 1 |
Barg, J; Belcheva, MM; Coscia, CJ; Johnson, FE; Levy, R; McHale, RJ; McLachlan, JA; Vogel, Z | 1 |
Gergen, KA; Kastin, AJ; Paul, D; Zadina, JE | 1 |
Cuadra, G; Molina, VA; Zurita, A | 1 |
Folk, JE; Isgor, C; Rice, KC; Torregrossa, MM; Watson, SJ; Woods, JH | 1 |
Aydin, S; Beis, R; Herekman-Demir, T; Oztürk, Y | 1 |
Falcon, E; Hill-Smith, TE; Lucki, I; Maier, K; Robinson, SA | 1 |
Arranz, B; Arrojo, M; Becoña, E; Bernardo, M; Castells, X; Cunill, R; Flórez, G; Fonseca, F; Garriga, M; Goikolea, JM; González-Pinto, A; López, A; Sáiz, PA; San, L; Tirado-Muñoz, J; Torrens, M; Zorrilla, I | 1 |
6 review(s) available for naltrexone and desipramine
Article | Year |
---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic | 2000 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Preclinical evaluation of the effects of buprenorphine, naltrexone and desipramine on cocaine self-administration.
Topics: Animals; Buprenorphine; Cocaine; Desipramine; Humans; Macaca mulatta; Naltrexone; Self Administration | 1990 |
Multiple endogenous opiate and non-opiate analgesia systems: evidence of their existence and clinical implications.
Topics: Acupuncture Therapy; Analgesia; Animals; Cholecystokinin; Conditioning, Classical; Desipramine; Dimethyl Sulfoxide; Drug Interactions; Electroshock; Endorphins; Enkephalin, Leucine; Mecamylamine; Morphine; N-Methylscopolamine; Naloxone; Naltrexone; Norepinephrine; Proglumide; Rats; Receptors, Cell Surface; Receptors, Cholecystokinin; Scopolamine; Scopolamine Derivatives; Serotonin; Spinal Cord | 1986 |
Clinical investigations of drug effects in women.
Topics: Buprenorphine; Cocaine; Desipramine; Female; Heroin Dependence; Humans; Male; Naltrexone; Opioid-Related Disorders; Sex Factors; Substance-Related Disorders | 1986 |
Clinical practice guideline on pharmacological and psychological management of adult patients with an anxiety disorder and comorbid substance use.
Topics: Adult; Anxiety Disorders; Desipramine; Humans; Naltrexone; Paroxetine; Substance-Related Disorders | 2022 |
20 other study(ies) available for naltrexone and desipramine
Article | Year |
---|---|
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cell Line; Cell Membrane Permeability; Central Nervous System Agents; Dogs; Drug Delivery Systems; Permeability; Pharmaceutical Preparations | 2002 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Serotonergic and catecholaminergic reuptake inhibitors have opposite effects on the ultrasonic isolation calls of rat pups.
Topics: Animals; Body Temperature; Catecholamines; Citalopram; Clomipramine; Desipramine; Flumazenil; Mazindol; Motor Activity; Naltrexone; Nortriptyline; Paroxetine; Piperidines; Rats; Rats, Inbred Strains; Serotonin Antagonists; Stress, Psychological; Ultrasonics; Vocalization, Animal | 1990 |
Chronic desipramine attenuates morphine analgesia.
Topics: Analgesics, Opioid; Animals; Desipramine; Drug Interactions; Male; Mice; Morphine; Naloxone; Naltrexone; Propranolol; Reaction Time | 1986 |
Opioids inhibit endothelin-mediated DNA synthesis, phosphoinositide turnover, and Ca2+ mobilization in rat C6 glioma cells.
Topics: Animals; Antibodies, Anti-Idiotypic; beta-Endorphin; Calcium; Desipramine; DNA, Neoplasm; Dose-Response Relationship, Drug; Endothelins; Glioma; Morphine; Naltrexone; Phosphatidylinositols; Rats; Receptors, Opioid; Thymidine; Tumor Cells, Cultured | 1994 |
mu-Opioid receptors modulate noradrenaline release from the rat hippocampus as measured by brain microdialysis.
Topics: Analgesics; Animals; Benzeneacetamides; Chromatography, High Pressure Liquid; Desipramine; Electrochemistry; Enkephalin, D-Penicillamine (2,5)-; Enkephalins; Extracellular Space; GTP-Binding Proteins; Hippocampus; Male; Microdialysis; Morphine; Naltrexone; Nerve Endings; Norepinephrine; Potassium; Pyrrolidines; Rats; Rats, Wistar; Receptors, Opioid, mu; Virulence Factors, Bordetella | 1994 |
A monoclonal anti-idiotypic antibody to opioid receptors labels desipramine-induced opioid binding sites on rat C6 glioma cells and attenuates thymidine incorporation into DNA.
Topics: Animals; Antibodies, Monoclonal; Brain Neoplasms; Cell Division; Cell Membrane; Colorimetry; Densitometry; Desipramine; DNA, Neoplasm; Glioma; Immunohistochemistry; Morphine; Naltrexone; Pertussis Toxin; Rats; Receptors, Opioid; Thymidine; Tumor Cells, Cultured; Virulence Factors, Bordetella | 1994 |
Intrathecal Tyr-W-MIF-1 produces potent, naloxone-reversible analgesia modulated by alpha 2-adrenoceptors.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Amino Acid Sequence; Animals; Desipramine; Dose-Response Relationship, Drug; Injections, Spinal; Male; Mice; Molecular Sequence Data; MSH Release-Inhibiting Hormone; Naloxone; Naltrexone; Narcotic Antagonists; Norepinephrine; Receptors, Adrenergic, alpha-2; Yohimbine | 1996 |
The involvement of an opiate mechanism in the sensitized behavioral deficit induced by early chronic variable stress: influence of desipramine.
Topics: Adrenergic Uptake Inhibitors; Animals; Arousal; Brain; Desipramine; Electroshock; Escape Reaction; Helplessness, Learned; Male; Naltrexone; Rats; Rats, Wistar; Receptors, Opioid | 1999 |
The delta-opioid receptor agonist (+)BW373U86 regulates BDNF mRNA expression in rats.
Topics: Analysis of Variance; Animals; Anti-Anxiety Agents; Antidepressive Agents; Behavior, Animal; Benzamides; Brain; Brain-Derived Neurotrophic Factor; Bupropion; Desipramine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Tolerance; Gene Expression Regulation; Immobilization; In Situ Hybridization; Male; Midazolam; Naltrexone; Narcotic Antagonists; Piperazines; Rats; Rats, Sprague-Dawley; Receptor, trkB; Receptors, Opioid, delta; RNA, Messenger; Swimming; Time Factors; Up-Regulation | 2004 |
The involvement of endogenous opioid mechanisms in the antinociceptive effects induced by antidepressant drugs, desipramine and trimipramine.
Topics: Analgesics; Animals; Antidepressive Agents; Desipramine; Male; Mice; Morphine; Naloxone; Naltrexone; Receptors, Opioid; Receptors, Opioid, delta; Trimipramine | 2006 |
Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Behavior, Animal; Buprenorphine; Depression; Desipramine; Dopamine; Male; Mice; Mice, Inbred C57BL; Motor Activity; Naltrexone; Narcotics; Nucleus Accumbens; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Swimming | 2015 |